Multi-trait GWAS of atherosclerosis detects novel pleiotropic loci - Bellomo, Tiffany R.; Bone, William P.; Chen, Brian Y.; Gawronski, Katerina A. B.; Zhang, David; Park, Joseph; Levin, Michael; Tsao, Noah; Klarin, Derek; Lynch, Julie; Assimes, Themistocles L.; Gaziano, J. Michael; et al. (medRxiv, 2021)
Rationale Although affecting different arterial territories, the related atherosclerotic vascular diseases coronary artery disease (CAD) and peripheral artery disease (PAD) share similar risk factors and have shared pathobiology. Analysis of their shared genetic architecture, along with that of common risk factors, may identify novel common biology.Objective To identify novel pleiotropic genetic loci associated with atherosclerosis and provide a better understanding of biological pathways underlying atherosclerosis.Methods and Results Summary statistics from genome wide association studies (GWAS) of nine known atherosclerotic (CAD, PAD) or atherosclerosis risk factors (body mass index, smoking initiation, type 2 diabetes, low density lipoprotein (LDL), high density lipoprotein, total cholesterol, and triglycerides) were combined to perform 15 separate multi-trait genetic association scans which resulted in 31 unique novel pleiotropic loci not yet reported as genome-wide significant for their respective traits. Colocalization with single-tissue eQTLs identified 34 candidate causal genes across 14 of the detected signals. Notably, the signal between PAD and CAD at the VDAC2 locus (rs7088974) colocalized with VDAC2 expression in aorta and tibial artery tissues. Additionally, the signal between PAD and LDL at the PCSK6 locus (rs1531817) affects PCSK6 splicing in human liver tissue and induced pluripotent derived hepatocyte like cells.Conclusions Joint analysis of related atherosclerotic disease traits and their risk factors allowed identification of unified biology that may offer the opportunity for therapeutic manipulation. VDAC2 and PCSK6 represent possible shared causal biology where existing inhibitors may be able to be leveraged for novel therapies.Competing Interest StatementS.M.D. receives research support to his institution from CytoVAS and RenalytixAI. S.K. is a founder of Maze Therapeutics, Verve Therapeutics and San Therapeutics. He holds equity in Catabasis and San Therapeutics. He is a member of the scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, NovoNordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Huag Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest and Medscape; and reports patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). C.J.O. is employed by Novartis Institutes of Biomedical Research. All other authors have no conflicts of interest to declare.Clinical TrialThe analysis in this manuscript was performed on publicly available data from human subject studies.Funding StatementThis research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by awardno. MVP000. This publication does not represent the views of the Department of Veteran Affairs or the United States Government. This research was also supported by funding from: the Department of Veterans Affairs awards nos. I01-BX03340 (K.C. and P.W.F.W.), I01-BX003362 (P.S.T. and K.M.C) and IK2-CX001780 (S.M.D.), the National Institutes of Health (DK101478 and DK126194 to B.F.V.), the American Heart Association (20PRE35120109 to W.P.B.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and determined to be exempt by the Veteran's Association Central IRB. All data used in this manuscript were publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full summary level association data from the MVP trans-ancestry PAD meta-analysis from this report are available through dbGAP, accession code phs001672. Additional data that support the findings of this study are available on request from the corresponding author (S.M.D.); these data are not publicly available due to U.S. Government and Department of Veteran's Affairs restrictions relating to participant privacy and consent. Data contributed by CARDIoGRAMplusC4D investigators are available online (http://www.CARDIOGRAMPLUSC4D.org/). The genetic and phenotypic UK Biobank data are available upon application to the UK Biobank. Additional data that were used to generate the Figures in this study are available on request from the corresponding author (S.M.D.) or through dbGAP as listed above. http://www.CARDIOGRAMPLUSC4D.org/ https://github.com/Bellomot/Athero_NGWAMA_Multitrait_GWAS